Skip to content

Funding
Launch
Partnership
Acquisition
Policy
Exit & IPO

CONNECTA Therapeutics

Spanish Biotech CONNECTA Therapeutics Advances Rare Disease Program with Phase IIa Trial Launch

June 10, 2026 by Marco Bianchi

CONNECTA Therapeutics starts Phase IIa clinical trial with CTH120 for Fragile X Syndrome

Categories Launch Tags CONNECTA Therapeutics, Healthtech, Spain Leave a comment

Browse by Country

Latest

Swedish freight tech company Einride lists on Nasdaq New York in major milestone for European mobility sectorJun 10, 2026

Capsa AI Secures $18M Series A to Expand AI Platform for Private Capital MarketsJun 10, 2026

Polish cybersecurity firms DC9 Cyber and Efigo join EU Cybersecurity Reserve following ENISA tender winJun 10, 2026

Romanian Logistics Platform SAMEDAY Expands Social Impact with New NGO Donation FeatureJun 10, 2026

Corgi Founder Opens Up About Extreme Work Culture, Sleeping in Office and Seven-Day Work WeeksJun 10, 2026

EU Markets

AI Infrastructure Billions, Banking Consolidation, and a SpaceX IPO Frenzy: What Europe's Financial Markets Mean for Startups This WeekJun 5, 2026

AI, Regulation, and Capital Shifts: What Europe's Financial Markets Mean for Your Startup This WeekMay 29, 2026

AI Debt Warnings, Blockchain Settlements, and Market Volatility: What European Founders Need to Know This WeekMay 23, 2026

Defence Tech Surges, Unicorns Emerge, and Europe's AI Funding Story Keeps Getting BiggerMay 22, 2026

EU Startups News

• About Us • Privacy Policy

Follow Us

LinkedIn X / Twitter Facebook

Stay informed

Get the latest European startup news delivered to your inbox every week. For broader markets news, visit: EU Finance News

No spam. Unsubscribe anytime.

By continuing to use this site you agree to our Privacy Policy and the use of cookies.

© 2026 EU Startups News • Built with GeneratePress

By continuing to use this site you agree to our Privacy Policy and the use of cookies.